⁦.⁩ walking us though endpoints in smoldering myeloma. Kicking off an amazing 2nd day of this meeting. ⁦Myeloma Society⁩ #mmsm

Incredible IMS IMWG Smoldering Myeloma Workshop in which no one left the room for 2 days.

Two fantastic stories published ~a year apart with striking confluence in findings - while age is the single most important risk factor for cancer, aging can also limit the ability of cells to undergo neoplastic transformation. nature.com/articles/s4158… nature.com/articles/s4358…

Very cool move from J&J to invest on the Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform technology...

Preservation of Autophagy May Be a Mechanism Behind Healthy Aging Aging Cell onlinelibrary.wiley.com/doi/10.1111/ac…

Unstructured serum electrophoresis data limits real world AI models in multiple myeloma: Evaluation of 384 institutions across United States [Nov 3, 2025] Ehsan Malek et al. #ASH25 abs25-11278 PID 2809 meetings-api.hematology.org/api/abstract/v… #mmsm #cancerdisparities #hpeonc

Elevated circulating tumor cells [#cactc] reflect high proliferation and genomic complexity in multiple myeloma [Sep 23, 2025] Garces et al. HemaSphere Journal (IF = 14.6) onlinelibrary.wiley.com/doi/10.1002/he… #mmsm #cagenome

#Myeloma Paper of the Day: Study of malignant transformation in myeloma-initiating cells finds 1qAmp originates from CD24-FCRL5+ B-cells, del 17p occurs at plasma cell stage, & FCRL5 facilitated malignant plasma cells via interaction w/ IRF4/SPI1: pubmed.ncbi.nlm.nih.gov/41259534/. #mmsm

What an honor to present Mayo Clinic Comprehensive Cancer Center grand rounds and to start my day with meeting the legend Dr Kyle and hanging out with the greatest Vincent Rajkumar and Shaji Kumar 🙏

We are honored to invite ⁦David Steensma, MD⁩ today as our guest speaker for the center of early detection and interception retreat #CHIP #MGUS ⁦Dana-Farber⁩

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants [Nov 3, 2025] Rajanna et al. C. Ola Landgren, M.D. #ASH25 abs25-11635 PID 4008 meetings-api.hematology.org/api/abstract/v… #mmsm #AI #oncopath

A tour de force by ⁦David Steensma, MD⁩ on the history and origin of a “clone” in the early detection and interception retreat ⁦Dana-Farber⁩

newyorker.com/culture/the-we…

Tatiana Schlossberg, the daughter of Caroline Kennedy, had just given birth when she was diagnosed with a rare form of leukemia. She writes about her fear of adding another tragedy to her family’s life. newyorkermag.visitlink.me/CLpbsb

I found this a really useful resource paper in Nature Rev Immunol Guidelines for T cell nomenclature nature.com/articles/s4157… The authors propose a new “modular” nomenclature that accounts for the increasing heterogeneity of T cell subtypes unearthed by recent single cell analyses.

Artificial intelligence in hematology Aziz Nazha Blood Journals Portfolio ashpublications.org/blood/article/…

#ASH25 Late Breaking abstracts are out! 1/ inMMyCAR, FIH of KLN-1010 in vivo BCMA CAR #mmsm meetings-api.hematology.org/api/abstract/v… marivi mateos Majestec-3 Ph.3 tec+dara vs investigator’s choice in #RRMM meetings-api.hematology.org/api/abstract/v… BRUIN-313, Ph. 3 pirto vs. BR in CLL/SLL meetings-api.hematology.org/api/abstract/v…

INCREDIBLE #ASH25 LBA by marivi mateos Luciano J Costa et al. bsAbs stealing the show across #MMsm LoT! As we all admire MajesTEC-3 PFS HR, I'll add the key reason IMO this was possible: Q4W tec dosing & primary IVIG PPx. Fewer Gr3+ infxns ➡️ stay on bsAb/CD38 longer ➡️ victory 👏

Looking forward to seeing the data on teclistamab and daratumumab in MajesTEC-3 presented at #ASH25 by marivi mateos Luciano J Costa . The study population of 1-3 prior lines, prior PI and IMiD, and control arm of dara pom dex or dara Vel dex is similar to CARTITUDE-4 with cilta-cel

Luciano J Costa Johnson & Johnson Congrats Luciano!